Flamma SpA, a Italy-headquartered contract manufacturer of small-molecule active pharmaceutical ingredients, will formally open its new cGMP workshop and Research and Development (R&D) Center in Dalian, China on June 19, 2017. The investment of $20 million brings the total capacity of Flamma’s Chinese operations in Dalian to 200 cubic meters and brings the R&D group to the same campus for increased efficiency and productivity.

The company has other expansions underway. By 2018, Flamma intends to spend $5 million to expand its R&D capabilities with the addition of a new R&D building at its headquarters in Chignolo d’Isola, Italy. By 2020, Flamma plans to increase its production capacity by 40% with the addition of another cGMP workshop at its Chignolo d’Isola headquarters.

Source: Flamma